1Wadelius M, Chen L Y, Eriksson N, et al. Association of warfarin dose with genes involved in its action and metabolism[ J]. Hum Genet, 2007,121 ( 1 ) :23.
2Sconce E A, Daly A K, Khan T I, et al. APOE genotype makes a small contribution to warfarin dose requirements [ J ]. Pharmacogenet Genomics, 2006, 16 ( 8 ) :609-611.
3Kohnke H, Sorlin K, Granath G, et al. Warfarin dose related to apolipoprotein E (APOE) genotype[ J]. Eur J Clin Phanna- col, 2005,61 (5/6) :381-388.
4Bodin L, Verstuyft C, Tregouet D A, et al. Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of Blood, 2005,106( 1 ) : 135-140.
5Sconce E A, Khan T I, Wynne H A, et al. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient char- acteristics upon warfarin dose requirements: proposal for a new dosing regimen[ J]. Blood, 2005,106(7) :2329-2333.
6Aquilante C L, Langaee T Y, Lopez L M, et al. Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements [ J ]. Clin Pharmacol Ther, 2006,79 ( 4 ) : 291-302.
7Wadelius M, Sorlin K, Wallerman O, et al. Warfarin sensitivity related to CYP2C9, CYP3A5, ABCBI ( MDR1 ) and other factors [ J ]. Pharmacogenomics J, 2004,4 ( 1 ) :40-48.
8Kimura R, Miyashita K, Kokubo Y, et al. Genotypes of vitamin K epoxide reductase, gamma-glutamyl carboxylase, and cytochrome Pd50 2C9 as determinants of daily warfarin dose in Japanese patients [ J ]. Thromb Res, 2007,120 ( 2 ) : 181-186.
9Hanlon C S, Rubinsztein D C. Arginine residues at codons 112 and 158 in the apolipoprotein E gene correspond to the ancestral state in humans [ J ]. Atherosclerosis, 1995,112 ( 1 ) : 85-90.
10Pedersen J C, Berg K. Gene-gene interaction between the low density lipoprotein receptor and apolipoprotein E loci affects lipid levels[ J ]. Clin Genet, 1990,38 (4) :287-294.
